Investment bank Goldman Sachs downgraded MoonLake Immunotherapeutics from a Mixed to a Sell rating, signaling heightened caution on the biopharma’s near-term outlook. The downgrade, reported by TheFly, was issued when the shares were trading in the mid-teens range and reflects concerns about the company’s upcoming clinical milestones and broader sector volatility.

Despite Goldman’s cautious stance, MLTX shares surged by 9.6% on the day of the downgrade, demonstrating robust buying interest. Trading volume totaled 1.8 million shares, roughly one-third of the average daily volume of 5.7 million shares, suggesting that institutional players may be accumulating stock quietly rather than participating in heavy intraday swings.

MoonLake received favorable Type B meeting feedback from the FDA regarding its lead candidate for inflammatory skin disorders. Regulators indicated that the company can leverage existing clinical data to support a Biologics License Application, potentially eliminating the need for new trials and shortening the review timeline. This guidance materially reduces regulatory risk and accelerates the path to market.

Following the FDA update, HC Wainwright reaffirmed its Buy rating and lifted its price target to 32, underscoring confidence in the drug’s commercial potential. Needham also maintained a Buy opinion with a 20 price target, citing attractive valuation and the likelihood of a smooth BLA submission process. These endorsements provide a counterbalance to Goldman Sachs’ Sell call and underscore divergent views among Wall Street strategists.